Risk of Leukaemia, Carcinoma, and Myelofibrosis in ³²P- or Chemotherapy-Treated Patients with Polycythaemia Vera: a Prospective Analysis of 682 Cases

References

• Lawrence J. H., Winchell H. S., Donald W. G. Leukemia in polycythemia vera. Relationship to splenic myeloid metaplasia and therapeutic radiation dose. Ann. Int. Med. 1969; 70: 763–771
   PubMed Web of Science ®Google Scholar
• Osgood E. E. Polycythemia vera: age relationship and survival. Blood 1965; 26: 243–256
   PubMed Web of Science ®Google Scholar
• Landaw S. A. Acute leukemia in Polycythemia Vera. Semin. in Hemat. 1986; 23: 156–165
   PubMed Web of Science ®Google Scholar
• Modan B., Lilienfeld A. H. Polycythemia vera and leukemia: the role of radiation treatment. Medicine 1965; 44: 305–320
   PubMed Web of Science ®Google Scholar
• Tubiana M., Flamant R., Attie E., Hayat M. A study of hematological complications occuring in patients with polycythemia vera treated by 32P, based on a series of 296 patients. Blood 1968; 32: 536–548
   PubMed Web of Science ®Google Scholar
• Moore C. V. Polycythemia vera complicated by acute leukemia. Ann. J. Med. 1967; 42: 949–957
   PubMed Web of Science ®Google Scholar
• Berk P. D., Wasserman L. R., Fruchman S. M., Goldberg J. D. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. Polycythemia Vera and the Myeloproliferative disorders, L. R. Wasserman, P. D. Berk. W. B. Saunders, Berlin 1995; 166–194
   Google Scholar
• Najean Y., Arrago J. P., Rain J. D., Dresch C. The “spent” phase of polycythaemia vera. Brit. J. Haemat. 1984; 56: 163–170
   PubMed Web of Science ®Google Scholar
• Silverstein M. N. Post polycythemia myeloid metaplasia. Arch. Int. Med. 1974; 134: 113–120
   PubMed Web of Science ®Google Scholar
• Najean Y., Rain J. D., Toubert M. E. group e français d'é-tude des polyglobulies, (1993) Traitement des polyglobulies par 32P avec ou sans traitement d'entretien par hydroxy-urée. Presse. Med., 22: 1951–1956
   PubMedGoogle Scholar
• Najean Y. Traitement des polyglobulies par hydroxy-urée ou pipobromanu. Presse. Med. 1992; 21: 1753–1757
   PubMed Web of Science ®Google Scholar
• Simon R. Randomized clinical trials in oncology. Cancer 1994; 74: 2614–2619
   PubMed Web of Science ®Google Scholar
• Tobias J. S., Houghtors J. Is informed consent essential for all chemotherapy studies?. Eur. J. Cancer. 1994; 30A: 897–899
   PubMed Web of Science ®Google Scholar
• Williams C. J., Zwitter M. Informed consent in european multi-centre randomized clinical trials. Are patients really informed. Eur. J. Cancer. 1994; 30A: 907–910
   PubMed Web of Science ®Google Scholar
• Benson A. B., Pregler J. P., Bean J. A., Rademaker A. W., Eshler B., Anderson K. Oncologists reluctance to accrue patients onto clinical trials. J. Clin. Oncol. 1991; 9: 2067–2075
   PubMed Web of Science ®Google Scholar
• Guyatt G. H., Sackett D. L., Cook D. J. User's guide to the medical literature. JAMA 1993; 270: 2598–2601
   PubMed Web of Science ®Google Scholar
• Nowak R. Problems in clinical trials go far beyond misconduct. Science 1994; 264: 1538–1541
   PubMed Web of Science ®Google Scholar
• Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Brit. J. Cancer. 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Institut National de la Santé et de la Recherche Médicale: Statistique de mortalité en France pour 1990. Published in Med./Sc. 1992; 8: 863–865
   Google Scholar
• Parkin D. M., Pisani P., Ferlay J. Estimates of the worlwide incidence of eighteen major cancers in 1985. Int. J. Cancer. 1993; 54: 594–606
   PubMed Web of Science ®Google Scholar
• Pisani P., Parkin D. M., Ferlay J. Estimates of the worlwide mortality from 18 major cancers in 1985. Int. J. Cancer. 1993; 55: 891–903
   PubMed Web of Science ®Google Scholar
• Ganz P. A. Long-range effects of clinical trial intervention on quality of life. Cancer 1994; 74: 2620–2624
   PubMed Web of Science ®Google Scholar
• Olschewski M., Schulger G., Schumacher M., Altman D. G. Quality of life assessment in clinical cancer research. Brit. J. Cancer. 1994; 70: 1–5
   PubMed Web of Science ®Google Scholar
• Najean Y., Dresch C., Rain J. D. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Brit. J. Haemat. 1994; 86: 233–235
   PubMed Web of Science ®Google Scholar
• Stiller C. A. Centralised treatment, entry to trials and survival. Brit. J. Cancer. 1994; 70: 352–362
   PubMed Web of Science ®Google Scholar
• Najean Y., Deschamps A., Dresch C., Daniel M. T., Rain J. D., Arrago J. P. Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up. Cancer 1988; 61: 89–95
   PubMed Web of Science ®Google Scholar
• Bizzozero O. L., Jobson K. G., Ciocco A. Radiation related leukemia in Hiroshima and Nagasaki. N. Engl. J. Med. 1966; 274: 1095–1101
   PubMed Web of Science ®Google Scholar
• Rosner F., Grünwald H. Hodgkin's disease and acute leukemia. Report of 8 cases and review of the literature. Ann. Int. Med. 1975; 70: 763–771
   Google Scholar
• Berger R., Bernheim A., Flandrin G., Dresch C., Najean Y. Cytogenetic studies on acute non-lymphocytic leukemia following polycythemia vera. Cancer. Genet. Cytogenet. 1984; 12: 441–451
   Web of Science ®Google Scholar
• Fruchtman S. M., Wasserman L. R. Therapeutic recommendations for polycythemia vera. Polycythemia Vera and the Myeloproliferative disorders, L. R. Wasserman, P. D. Berk, N. L Berlin. W.B. Saunders publish. 1995; 337–349
   Google Scholar
• Landaw S. A. Acute leukemia in polycythemia vera, in Polycythemia Vera and the Myeloproliferative disorders, L. R. Wasserman, P. D. Berk, N. L Berlin. W. B. Saunders edit publish. 1995; 154–165
   Google Scholar
• Löfvenberg E., Wahlin A. Management of polycythemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Europ. J. Haemat. 1988; 41: 375–381
   PubMed Web of Science ®Google Scholar
• Sharon R., Tatarsky L, Ben-Arieh Y. Treatment of polycythemia vera with hydroxy-urea. Cancer 1986; 57: 718–720
   PubMed Web of Science ®Google Scholar
• Weinfeld A., Swolin B., Westin J. Acute leukemia after hydroxy-urea therapy in PV and allied disorders. Eur. J. Haemat. 1994; 52: 134–139
   PubMed Web of Science ®Google Scholar
• Boivin P. Indications, procedure and results for the treatment of PV by pipobroman and hydroxy-urea. Nouv. Rev. Fr. Hemat. 1993; 35: 491–498
   PubMedGoogle Scholar
• Brusamolino E., Salvaneschi L., Canevari A., Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J. Clin. Oncol. 1984; 2: 558–561
   PubMed Web of Science ®Google Scholar
• Nand S., Messmore H., Fischer S. G., Bird M. L., Schulz W., Fisher R. I. Leukemic transformation in PV: analysis of risk factors. Amer. J. Haemat. 1990; 34: 32–36
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J. Radiotherapy and chemotherapy induced myelodysplasia and acute myeloid leukemia. Leuk. Res. 1992; 16: 61–65
   PubMed Web of Science ®Google Scholar
• Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occuring after treatment of aplastic anemia. New. Engl. J. Med. 1993; 329: 1152–1157
   PubMed Web of Science ®Google Scholar
• Lowsky R., Lipton J., Fyles G., Minden M., Meharchand J., Tejpar I., Atkins H., Sutcliffe S., Messner H. Secondary malignancies after bone marrow transplantation in adults. J. Clin. Oncol. 1994; 12: 2187–2192
   PubMed Web of Science ®Google Scholar
• Najean Y., Mugnier P., Dresch C., Rain J. D. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Brit. J. Haemat. 1987; 67: 285–291
   PubMed Web of Science ®Google Scholar
• Simon R. Randomized clinical trials in oncology. Principles and obstacles. Cancer 1994; 74: 2614–2619
   PubMed Web of Science ®Google Scholar